neurology
Clinically Isolated Syndrome (CIS) Risk of MS
Estimates risk of conversion from clinically isolated syndrome (CIS) to clinically definite multiple sclerosis (CDMS) based on MRI and clinical features.
Score interpretation
Low risk of MS conversion (<30%)
→ Watchful waiting; repeat MRI at 6-12 months
Moderate risk of MS conversion (30-60%)
→ Discuss disease-modifying therapy; neurology review
High risk of MS conversion (>60%)
→ Early DMT initiation recommended (interferon beta, glatiramer, natalizumab)
Interpretation bands for the CIS Risk. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Dimethyl Fumarate · Disease-Modifying Therapy — Relapsing-Remitting Multiple Sclerosis
- Ocrelizumab · Multiple Sclerosis — Disease-Modifying Therapy
- Fingolimod · Multiple Sclerosis — Disease-Modifying Therapy
- Alemtuzumab · Multiple Sclerosis — Disease-Modifying Therapy
- Cladribine · Multiple Sclerosis — Disease-Modifying Therapy
- Ofatumumab · Multiple Sclerosis — Disease-Modifying Therapy
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.